In the News
ContagionLive interview: A Rapid Sepsis Diagnostic Test for Better Patient Outcomes
Nina Cosdon of ContagionLive interviewed the chief medical officer of Immunexpress Inc., Roy Davis, MD, PhD, MHA, in a post titled A Rapid Sepsis Diagnostic Test for Better Patient Outcomes. Sepsis diagnosis often takes days. Dr. Roy Davis and his team have developed a test that can diagnose sepsis in...
CEO Rolland Carlson: When Advancing a Medical Device, Be A Partner First & Seller Second to Hospital Systems
Immunexpress CEO Rolland Carlson was recently featured on HITConsultant, which provides healthcare technology news, analysis and insights for healthcare executives, physicians and providers. "US hospital systems validate the safety, clinical utility, and robustness of newly FDA-approved devices, 510(k) cleared, before adopting them into clinical practice. This work occurs alongside evaluating...
Interview with DocWireNew: Dr. Rollie Carlson, CEO, Immunexpress: Providing RAPID Detection for Sepsis
DocWire News spoke with Dr. Rollie Carlson, CEO of Immunexpress, to learn more about this cutting-edge technology, and how it can quickly and accurately detect sepsis, and lead to faster treatment. https://youtu.be/Vd0FL3fYPwY
Interview with Dr Rolland Carlson and Dr Richard Brandon
Download the Drug Target Review interview with Dr. Rolland Carlson and Dr. Richard Brandon.(pdf) The 2022 Drug Target Review Assays ebook, includes an interview about our sepsis detection initiative. In this collection of articles, Dr. Rolland Carlson and Dr. Richard Brandon, Immunexpress, answer questions about molecular...
A Paradigm Shift in Sepsis Diagnostics
By Anna MacDonald of Technology Networks Immunexpress is advancing next-generation clinical sepsis diagnosis tests for use in emergency room and intensive care unit settings. The company’s lead test SeptiCyte® RAPID is clinically validated and has received 510(k) FDA clearance indicated for the diagnosis of sepsis in adults. It is the...
Tips For Obtaining Your 510(k) FDA Clearance
By Rolland Carlson, Ph.D., CEO, Immunexpress Our SeptiCyte RAPID clinical test received 510(k) FDA clearance indicated for the diagnosis of sepsis in adults. Sepsis is a life-threatening medical condition. Every minute counts for these patients in the ER and ICU. Clinicians in these settings need processes to distinguish sepsis patients...
DNA Weekly: Discussing Sepsis Diagnosis with Immunexpress
Immunexpress is a molecular diagnostic company focused on improving outcomes for suspected sepsis patients. In this interview CEO Dr. Rollie Carlson discusses the company’s FDA-cleared sepsis diagnostic test and the value it brings to the healthcare system.
SeptiCyte RAPID is highlighted in this 10News First Brisbane interview. The country's largest pediatric sepsis study at the Queensland Children's Hospital is working on finding simple diagnostic blood tests for the 5,000 Australians a year and robs others of their limbs. https://vimeo.com/794332571
Finding The Product- Market Fit, with Rollie Carlson Ph.D. CEO of Immunexpress
Gurus, why should you have your engineers and researchers out in the field? How can they get a good product-market fit? What is the NOT INVENTED HERE factor and why should you avoid it? Dr. Carlson discusses this and more. Listen in as he provides further evidence that perfect should...
Molecular Dx Company Biocartis ‘At Inflection Point’ As It Eyes Infectious Disease Market
Executive Summary Belgian developer of cancer diagnostics is building an infectious disease portfolio on the back of its new SARS-CoV-2 test and collaborations with Immunexpress and Endpoint Health.
SCCM Podcast: Severe COVID-19 and Sepsis
Severe COVID-19 infection can be a form of viral sepsis with occasionally concomitant bacterial infection. Pamela M. Peeke MD, MPH, FACP, FACSM, is joined by Russell Miller, MD, MPH, FCCM, to discuss the definition of sepsis and overlap with case descriptions of patients with severe COVID-19, how experience with viral...
Biocartis announces market release of SeptiCyte RAPID test on Idylla
Biocartis Group has released of SeptiCyte RAPID on Idylla as a CE-marked IVD test. SeptiCyte RAPID is a host-response test that distinguishes sepsis from non-infectious systemic inflammation in patients suspected of sepsis and provides actionable results in about one hour.